Prisoners in Massachusetts are not being given expensive new medications to treat hepatitis C, according to a prisoner rights group that is suing the state, WBUR’s Martha Bebinger reports:
The lawsuit says new drugs that can cure Hep C are now standard care, especially for patients at risk of death from the disease. It’s not clear how many of the 1,500 state prisoners with Hep C are in an advanced stage that would warrant use of the $80,000-90,000 treatment.
But Joel Thompson at Prisoners’ Legal Services says all prisoners are entitled to adequate medical care under the Constitution.
“And the treatment of Hepatitis C, given all the changes that have come, in the treatment of the disease, is no longer adequate. It violates their constitutional rights,” Thompson says.
There is no comment yet from the state or the private group that handles prison medical care.
Here’s the full news release from Prisoners’ Legal Services and the National Lawyers Guild:
Hundreds of prison inmates are in danger of losing their lives because the Department of Correction refuses to provide the medicine that will cure their potentially fatal disease. A class action lawsuit filed in federal court today by lawyers for the National Lawyers Guild and Prisoners Legal Services says it is Massachusetts’ legal responsibility to provide adequate medical care to state prisoners. Urszula Masny-Latos, Executive Director of the Massachusetts chapter of the National Lawyers Guild, said: “It is the responsibility of the state, which spends millions to incarcerate thousands of people, to provide adequate medical care for them. Without such care, many of them will develop serious complications of this disease, and some will die. These people were sentenced to incarceration, not to death.” The lawsuit seeks to compel the Department of Correction (DOC) and its health care contractor, the Massachusetts Partnership for Correctional HealthCare, LLC (MPCH) to provide inmates in their custody with new, lifesaving medications for Hepatitis CHepatitis C, an infectious disease which causes progressive damage to the liver and ultimately liver failure, is widely prevalent in prisons and jails. New medications approved by the FDA in 2014 represent a dramatic improvement over their predecessors, curing nearly one hundred percent of patients, with far fewer side effects. The DOC and MPCH have stopped using the now-outdated medications, but have failed and refused to provide prisoners with the new treatment. Continue reading